title: [Intensity-modulated radiation therapy (IMRT) for localized and locally advanced prostate cancer: initial result and morbidity].
abstract: OBJECTIVE
  We report the short-term results of intensity modulated radiotherapy (IMRT) for localized and locally advanced prostate cancer.
  
  
  METHODS
  The study was conducted on the total of 53 patients receiving IMRT in our hospital from July 2007 to November 2010 (25 patients receiving IMRT alone and 28 patients receiving neoadjuvant hormone therapy before IMRT).
  
  
  RESULTS
  The period of neoadjuvant hormone therapy was 1 to 29 months (median 7 months). 6 patients were in the low risk group, 15 in the intermediate risk group, and 32 in the high risk group according to the D'Amico risk classification criteria. With the prescribed dose of 70 Gy to 74 Gy, prostates were irradiated locally. The follow-up period was 18 to 48 months (median 30 months). The overall 3-year PSA relapse-free survival rate was 90.0%. The 3-year PSA relapse-free survival rate for the patients in low-, intermediate- and high-risk groups were 80.0%, 93.3% and 90.0%, respectively. The 3-year PSA relapse-free survival rate based on the presence or absence of neoadjuvant hormone therapy were 95.8% and 81.7%. respectively. Acute-phase adverse events (NCI/CTCAE) were observed in 32 patients (60.4%), and all were grade 1 or 2. No late adverse events were observed.
  
  
  CONCLUSIONS
  IMRT is possible treatment for localized and locally advanced prostate cancer without high-grade toxicity. We continue to evaluate the efficacy and durability of IMRT.
authors.affiliation: Department of Urology, NTT West Osaka Hospital.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Ohzeki
authors.forename: Shogo
authors.initials: S
authors.lastname: Adomi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Koike
authors.forename: Atsunobu
authors.initials: A
authors.lastname: Esa
authors.forename: Syoichi
authors.initials: S
authors.lastname: Fukud
authors.forename: Yuji
authors.initials: Y
authors.lastname: Yamada
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D050397:Radiotherapy, Intensity-Modulated; D016896:Treatment Outcome